Trial Profile

A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF NXT007 IN HEALTHY VOLUNTEERS AND PATIENTS WITH HEMOPHILIA A (NXTAGE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NXT 007 (Primary)
Indications Haemophilia A
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Acronyms NXTAGE
Sponsors Chugai Pharmaceutical

23 Jun 2025 According to Roche media release, company presented result data from the primary analysis of this study at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress, 21-25 June, Washington D.C., United States.
23 Jun 2025 Positive results from this study supporting its progression into phase III clinical development presented in the Roche Media Release.
31 Aug 2022 Planned number of patients changed from 76 to 106.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com